SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

September 27, 2011 07:00 ET

Onko-Sure® Is National Sponsor for Get Your Rear in Gear® Colorectal Cancer Grassroots Organization

Sponsoring Message of Patient Empowerment and Individual Health Advocacy to Reach a Nationwide Audience

TUSTIN, CA--(Marketwire - Sep 27, 2011) - Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has signed a Collaboration Agreement with the Colon Cancer Coalition, which operates Get Your Rear in Gear, a series of events nationwide aimed at encouraging individual health advocacy.

Get Your Rear in Gear® organizes and conducts the largest national series of 5K races for colon cancer awareness and prevention in North America. Races will be held in nearly 40 major cities in 2011, with an estimated 30,000 race participants per year, and the numbers continue to grow. www.GetYourRearInGear.com is a source of optimistic, inspirational, and proactive information for colorectal cancer patients, survivors, their families, and their loved ones.

Per the terms of the Collaboration Agreement, Radient Pharmaceuticals' Onko-Sure® will sponsor Get Your Rear in Gear's national digital video campaigns that convey the compelling message of patient awareness, responsibility, education, and activism to the group's grassroots network. Digital videos will be sent to Get Your Rear in Gear's membership and will be used to expand the organization's message nationally and regionally to support 5K races across the U.S. Videos will contain a brief informational ad regarding Onko-Sure® and its efficacy in the early detection of colorectal cancer recurrence.

Carcinoembryonic antigen (CEA) is currently the Standard of Care in the detection of colorectal cancer recurrence. Onko-Sure® is an FDA-cleared blood test for treatment monitoring and recurrence monitoring of colorectal cancer. Recent studies have shown that the combined use of Onko-Sure® and CEA increased the test sensitivity to 55% higher than that of CEA alone.

"We're a fast-growing organization with a passion for empowering people to get screened for early cancer detection. Our message is that of optimism and the power of knowing that we have control in our lives and in our own health," said Get Your Rear in Gear's Founder and President, Kristin Tabor. "I started this organization looking to spread the message that testing and early detection can make the ultimate difference with this disease. The Coalition deploys all locally-raised funds to increase awareness and screening in each of our race markets."

"Get Your Rear in Gear is excited to collaborate with Radient, and we are happy to help share the news that Onko-Sure® can detect recurrence earlier and potentially add years to a survivor's life," concluded Tabor.

"Get Your Rear In Gear's proactive message is one that we wholeheartedly support. Patients are becoming increasingly self-educated about their health and their choices. We are reaching out to them, as well as to their doctors who support patients by participating in Get Your Rear in Gear 5K races. We're excited to embark upon this sponsorship and we look forward to a long-term collaborative relationship with Get Your Rear in Gear," stated Radient Chairman and CEO Douglas MacLellan.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.

The following table is intended to provide the latest information on Radient's business metrics:

RPC's Business Metrics
Cash on hand: $415,000*
*Approximate amount as of September 23, 2011
Shares Outstanding: 547 million*
*Approximate number as of September 23, 2011
750 million shares authorized.
Outstanding Warrants & Options: 111 million*
*Approximate number as of September 23, 2011

About the Colon Cancer Coalition and Get Your Rear in Gear®

The Colon Cancer Coalition was formed in 2006 to oversee the continued success of Get Your Rear in Gear® events nationally. The Coalition is a volunteer-driven organization promoting awareness, raising funds, working to educate the public and work toward prevention of colon cancer. Get Your Rear in Gear events are designed to unite people across the country to provide support and hope for those who have had their lives affected by our nation's second leading cause of cancer deaths, and to encourage individuals of all ages to get screened, live healthy lifestyles, and become advocates for their own health. For more information visit www.getyourrearingear.com.

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.